Cell-autonomous GP130 activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment
Sternberg, C.; Limberger, T.; Raigel, M.; Trachtova, K.; Schlederer, M.; Lindner, D.; Kodajova, P.; Yang, J.; Ziegler, R.; Neubauer, H. A.; Dey, S.; Redmer, T.; Stoiber, S.; Hejret, V.; Tichy, B.; Tomberger, M.; Harbusch, N. S.; Tangermann, S.; Oberhuber, M.; Bystry, V.; Persson, J. L.; Pospisilova, S.; Wolf, P.; Sternberg, F.; Hoegler, S.; Lagger, S.; Rose-John, S.; Kenner, L.
Show abstract
Prostate cancer ranks as the second most frequently diagnosed cancer in men worldwide. Recent research highlights the crucial roles GP130-mediated signaling pathways play in the development and progression of various cancers, particularly through hyperactivated STAT3 signaling. Here, we find that genetic cell-autonomous activation of the GP130 receptor in prostate epithelial cells triggers active STAT3 signaling and significantly reduces tumor growth in vivo. Mechanistically, genetic activation of GP130 signaling mediates senescence via the STAT3/ARF/p53 axis and anti-tumor immunity via recruitment of cytotoxic T-cells, ultimately impeding tumor progression. In prostate cancer patients, high GP130 mRNA expression levels correlate with better recurrence-free survival, increased senescence signals and a transition from an immune-cold to an immune-hot tumor. Our findings reveal a context-dependent role of GP130/STAT3 in carcinogenesis and a tumor-suppressive function in prostate cancer development. We challenge the prevailing concept of blocking GP130/STAT3 signaling as functional prostate cancer treatment and instead propose cell-autonomous GP130 activation as a novel therapeutic strategy.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Disassembly of hemidesmosomes promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin into focal adhesions 96%
- AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer 96%
- A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer 96%
Similar papers in this journal
- Role of Specialized mSWI/SNF Complexes in Prostate Cancer Lineage Plasticity 97%
- Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer 96%
- The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact 95%
Similar papers in this journal
- ECM-free patient-derived organoids preserve diverse prostate cancer lineages and uncover in vitro-enriched cell types 96%
- Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer 96%
- Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancer 93%
Similar papers in this journal
- Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer 95%
- Multi-omics evaluation of cell lines as models for metastatic prostate cancer 94%
- Single-cell transcriptional profiling of clear cell renal cell carcinoma reveals an invasive tumor vasculature phenotype 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.